The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Expansion cohort results of RAGNAR: erdafitinib in CCA with FGFR alterations
Erdafitinib is an oral selective pan-FGFR tyrosine kinase inhibitor which is approved to treat patients with locally advanced or metastatic urothelial carcinoma and FGFR alterations. In this interview, Shubham Pant, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses results from the Phase II RAGNAR trial (NCT04083976) which evaluated the efficacy and safety of erdagitnib in adults with cholangiocarcinoma (CCA) with prespecified FGFR fusions or mutations. Erdagitnib demonstrated encouraging efficacy, with a manageable safety profile additionally reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
